スマートドラッグデリバリーシステムの世界市場 (2022～2031年)：製品別 (コネクテッド吸入器・コネクテッドオートインジェクター・コネクテッドペンインジェクター・コネクテッドウェアラブルインジェクター・アドオンセンサー・その他) 産業分析・規模・シェア・成長・動向・予測

当レポートでは、世界のスマートドラッグデリバリーシステムの市場を調査し、市場概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 序文

第2章 前提・調査手法

第3章 エグゼクティブサマリー：世界のスマートドラッグデリバリーシステム市場

第4章 市場概要

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会

第5章 主な洞察

• スマートインスリンペン：ブランド分析
• 米国で入手可能なインスリンペン型デリバリーデバイス
• 糖尿病のデジタル化に関する洞察：機会と課題
• 主要な産業イベント (提携・M&Aなど)
• COVID-19：影響分析

第6章 世界のスマートドラッグデリバリーシステム市場の分析・予測：製品別

• イントロダクション・定義
• 主な調査結果・展開
• 市場予測
  • コネクテッド吸入器
  • コネクテッドオートインジェクター
  • コネクテッドペンインジェクター
  • コネクテッドウェアラブルインジェクター
  • アドオンセンサー
  • その他
• 市場の魅力

第7章 世界のスマートドラッグデリバリーシステム市場の分析・予測：ドラッグデリバリーモード別

• イントロダクション・定義
• 主な調査結果・展開
• 市場予測
  • 注射
  • 吸入
  • 経口
• 市場の魅力

第8章 世界のスマートドラッグデリバリーシステム市場の分析・予測：治療分野別

• イントロダクション・定義
• 主な調査結果・展開
• 市場予測
  • 代謝障害
  • 神経障害
  • 呼吸器疾患
  • ホルモン障害
  • その他
• 市場の魅力

第9章 世界のスマートドラッグデリバリーシステム市場の分析・予測：エンドユーザー別

• イントロダクション・定義
• 主な調査結果・展開
• 市場予測
  • 病院
  • 診療所
  • 在宅ケア
  • 外来診療
  • その他
• 市場の魅力

第10章 世界のスマートドラッグデリバリーシステム市場の分析・予測：地域別

• 主な調査結果
• 市場予測
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ
• 市場の魅力

第11章 北米のスマートドラッグデリバリーシステム市場の分析・予測

第12章 欧州のスマートドラッグデリバリーシステム市場の分析・予測

第13章 アジア太平洋のスマートドラッグデリバリーシステム市場の分析・予測

第14章 ラテンアメリカのスマートドラッグデリバリーシステム市場の分析・予測

第15章 中東およびアフリカのスマートドラッグデリバリーシステム市場の分析・予測

第16章 競合情勢

• 参入企業の競合マトリックス
• 企業シェア分析
• 企業プロファイル
  • Abbott Laboratories
  • Adherium Ltd.
  • Amiko Digital Health Limited
  • Becton, Dickinson and Company
  • BIOCORP
  • CeQur Corporation
  • Cognita Labs
  • E3D Elcam Drug Delivery Devices
  • H&T Presspart Manufacturing Ltd.
  • HCmed Innovations Co., Ltd.
  • Medtronic plc
  • Novo Nordisk
  • Phillips-Medisize
  • Sonceboz

List of Tables

• Table 01: Smart Insulin Pen - Brand Analysis
• Table 02: Insulin Pen Delivery Devices Available in the United States
• Table 03: Global Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Product, 2017-2031
• Table 04: Global Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Drug Delivery Mode, 2017-2031
• Table 05: Global Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
• Table 06: Global Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by End-user, 2017-2031
• Table 07: Global Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Region, 2017-2031
• Table 08: North America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Product, 2017-2031
• Table 09: North America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Drug Delivery Mode, 2017-2031
• Table 10: North America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
• Table 11: North America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by End-user, 2017-2031
• Table 12: North America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Country, 2017-2031
• Table 13: Europe Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Product, 2017-2031
• Table 14: Europe Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Drug Delivery Mode, 2017-2031
• Table 15: Europe Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
• Table 16: Europe Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by End-user, 2017-2031
• Table 17: Europe Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
• Table 18: Asia Pacific Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Product, 2017-2031
• Table 19: Asia Pacific Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Drug Delivery Mode, 2017-2031
• Table 20: Asia Pacific Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
• Table 21: Asia Pacific Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by End-user, 2017-2031
• Table 22: Asia Pacific Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
• Table 23: Latin America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Product, 2017-2031
• Table 24: Latin America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Drug Delivery Mode, 2017-2031
• Table 25: Latin America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
• Table 26: Latin America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by End-user, 2017-2031
• Table 27: Latin America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
• Table 28: Middle East & Africa Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Product, 2017-2031
• Table 29: Middle East & Africa Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Drug Delivery Mode, 2017-2031
• Table 30: Middle East & Africa Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
• Table 31: Middle East & Africa Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by End-user, 2017-2031
• Table 32: Middle East & Africa Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

List of Figures

• Figure 01: Global Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, 2017-2031
• Figure 02: Global Smart Drug Delivery Systems Market Analysis and Forecast, by Product, 2021 and 2031
• Figure 03: Global Smart Drug Delivery Systems Market Attractiveness Analysis, by Product, 2022-2031
• Figure 04: Global Smart Drug Delivery Systems Market (US$ Mn), by Connected Inhalers, 2017-2031
• Figure 05: Global Smart Drug Delivery Systems Market (US$ Mn), by Connected Autoinjectors, 2017-2031
• Figure 06: Global Smart Drug Delivery Systems Market (US$ Mn), by Connected Pen Injectors, 2017-2031
• Figure 07: Global Smart Drug Delivery Systems Market (US$ Mn), by Connected Wearable Injectors, 2017-2031
• Figure 08: Global Smart Drug Delivery Systems Market (US$ Mn), by Add-on Sensors, 2017-2031
• Figure 09: Global Smart Drug Delivery Systems Market (US$ Mn), by Others, 2017-2031
• Figure 10: Global Smart Drug Delivery Systems Market Analysis and Forecast, by Drug Delivery Mode 2021 and 2031
• Figure 11: Global Smart Drug Delivery Systems Market Attractiveness Analysis, by Drug Delivery Mode, 2022-2031
• Figure 12: Global Smart Drug Delivery Systems Market (US$ Mn), by Injectable, 2017-2031
• Figure 13: Global Smart Drug Delivery Systems Market (US$ Mn), by Inhalation, 2017-2031
• Figure 14: Global Smart Drug Delivery Systems Market (US$ Mn), by Oral, 2017-2031
• Figure 15: Global Smart Drug Delivery Systems Market Analysis and Forecast, by Therapeutic Area, 2021 and 2031
• Figure 16: Global Smart Drug Delivery Systems Market Attractiveness Analysis, by Therapeutic Area, 2022-2031
• Figure 17: Global Smart Drug Delivery Systems Market (US$ Mn), by Metabolic Disorders, 2017-2031
• Figure 18: Global Smart Drug Delivery Systems Market (US$ Mn), by Neurological Disorders, 2017-2031
• Figure 19: Global Smart Drug Delivery Systems Market (US$ Mn), by Respiratory Disorders, 2017-2031
• Figure 20: Global Smart Drug Delivery Systems Market (US$ Mn), by Hormonal Disorders, 2017-2031
• Figure 21: Global Smart Drug Delivery Systems Market (US$ Mn), by Others, 2017-2031
• Figure 22: Global Smart Drug Delivery Systems Market Analysis and Forecast, by End-user, 2021 and 2031
• Figure 23: Global Smart Drug Delivery Systems Market Attractiveness Analysis, by End-user, 2022-2031
• Figure 24: Global Smart Drug Delivery Systems Market (US$ Mn), by Hospitals, 2017-2031
• Figure 25: Global Smart Drug Delivery Systems Market (US$ Mn), by Clinics, 2017-2031
• Figure 26: Global Smart Drug Delivery Systems Market (US$ Mn), by Home Care, 2017-2031
• Figure 27: Global Smart Drug Delivery Systems Market (US$ Mn), by Ambulatory Care Settings, 2017-2031
• Figure 28: Global Smart Drug Delivery Systems Market (US$ Mn), by Others, 2017-2031
• Figure 29: Global Smart Drug Delivery Systems Market Analysis and Forecast, by Region, 2021 and 2031
• Figure 30: Global Smart Drug Delivery Systems Market Attractiveness Analysis, by Region, 2022-2031
• Figure 31: North America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, 2017-2031
• Figure 32: North America Smart Drug Delivery Systems Market Analysis and Forecast, by Product, 2021 and 2031
• Figure 33: North America Smart Drug Delivery Systems Market Attractiveness Analysis, by Product, 2022-2031
• Figure 34: North America Smart Drug Delivery Systems Market Analysis and Forecast, by Drug Delivery Mode, 2021 and 2031
• Figure 35: North America Smart Drug Delivery Systems Market Attractiveness Analysis, by Drug Delivery Mode, 2022-2031
• Figure 36: North America Smart Drug Delivery Systems Market Analysis and Forecast, by Therapeutic Area, 2021 and 2031
• Figure 37: North America Smart Drug Delivery Systems Market Attractiveness Analysis, by Therapeutic Area, 2022-2031
• Figure 38: North America Smart Drug Delivery Systems Market Analysis and Forecast, by End-user, 2021 and 2031
• Figure 39: North America Smart Drug Delivery Systems Market Attractiveness Analysis, by End-user, 2022-2031
• Figure 40: North America Smart Drug Delivery Systems Market Analysis and Forecast, by Country, 2021 and 2031
• Figure 41: North America Smart Drug Delivery Systems Market Attractiveness Analysis, by Country, 2022-2031
• Figure 42: Europe Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, 2017-2031
• Figure 43: Europe Smart Drug Delivery Systems Market Analysis and Forecast, by Product, 2021 and 2031
• Figure 44: Europe Smart Drug Delivery Systems Market Attractiveness Analysis, by Product, 2022-2031
• Figure 45: Europe Smart Drug Delivery Systems Market Analysis and Forecast, by Drug Delivery Mode. 2021 and 2031
• Figure 46: Europe Smart Drug Delivery Systems Market Attractiveness Analysis, by Drug Delivery Mode, 2022-2031
• Figure 47: Europe Smart Drug Delivery Systems Market Analysis and Forecast, by Therapeutic Area, 2021 and 2031
• Figure 48: Europe Smart Drug Delivery Systems Market Attractiveness Analysis, by Therapeutic Area, 2022-2031
• Figure 49: Europe Smart Drug Delivery Systems Market Analysis and Forecast, by End-user, 2021 and 2031
• Figure 50: Europe Smart Drug Delivery Systems Market Attractiveness Analysis, by End-user, 2022-2031
• Figure 51: Europe Smart Drug Delivery Systems Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
• Figure 52: Europe Smart Drug Delivery Systems Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
• Figure 53: Asia Pacific Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, 2017-2031
• Figure 54: Asia Pacific Smart Drug Delivery Systems Market Analysis and Forecast, by Product, 2021 and 2031
• Figure 55: Asia Pacific Smart Drug Delivery Systems Market Attractiveness Analysis, by Product, 2022-2031
• Figure 56: Asia Pacific Smart Drug Delivery Systems Market Analysis and Forecast, by Drug Delivery Mode 2021 and 2031
• Figure 57: Asia Pacific Smart Drug Delivery Systems Market Attractiveness Analysis, by Drug Delivery Mode, 2022-2031
• Figure 58: Asia Pacific Smart Drug Delivery Systems Market Analysis and Forecast, by Therapeutic Area, 2021 and 2031
• Figure 59: Asia Pacific Smart Drug Delivery Systems Market Attractiveness Analysis, by Therapeutic Area, 2022-2031
• Figure 60: Asia Pacific Smart Drug Delivery Systems Market Analysis and Forecast, by End-user, 2021 and 2031
• Figure 61: Asia Pacific Smart Drug Delivery Systems Market Attractiveness Analysis, by End-user, 2022-2031
• Figure 62: Asia Pacific Smart Drug Delivery Systems Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
• Figure 63: Asia Pacific Smart Drug Delivery Systems Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
• Figure 64: Latin America Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, 2017-2031
• Figure 65: Latin America Smart Drug Delivery Systems Market Analysis and Forecast, by Product, 2021 and 2031
• Figure 66: Latin America Smart Drug Delivery Systems Market Attractiveness Analysis, by Product, 2022-2031
• Figure 67: Latin America Smart Drug Delivery Systems Market Analysis and Forecast, by Drug Delivery Mode, 2021 and 2031
• Figure 68: Latin America Smart Drug Delivery Systems Market Attractiveness Analysis, by Drug Delivery Mode, 2022-2031
• Figure 69: Latin America Smart Drug Delivery Systems Market Analysis and Forecast, by Therapeutic Area, 2021 and 2031
• Figure 70: Latin America Smart Drug Delivery Systems Market Attractiveness Analysis, by Therapeutic Area, 2022-2031
• Figure 71: Latin America Smart Drug Delivery Systems Market Analysis and Forecast, by End-user, 2021 and 2031
• Figure 72: Latin America Smart Drug Delivery Systems Market Attractiveness Analysis, by End-user, 2022-2031
• Figure 73: Latin America Smart Drug Delivery Systems Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
• Figure 74: Latin America Smart Drug Delivery Systems Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
• Figure 75: Middle East & Africa Smart Drug Delivery Systems Market Value (US$ Mn) Forecast, 2017-2031
• Figure 76: Middle East & Africa Smart Drug Delivery Systems Market Analysis and Forecast, by Product, 2021 and 2031
• Figure 77: Middle East & Africa Smart Drug Delivery Systems Market Attractiveness Analysis, by Product, 2022-2031
• Figure 78: Middle East & Africa Smart Drug Delivery Systems Market Analysis and Forecast, by Drug Delivery Mode, 2021 and 2031
• Figure 79: Middle East & Africa Smart Drug Delivery Systems Market Attractiveness Analysis, by Drug Delivery Mode, 2022-2031
• Figure 80: Middle East & Africa Smart Drug Delivery Systems Market Analysis and Forecast, by Therapeutic Area, 2021 and 2031
• Figure 81: Middle East & Africa Smart Drug Delivery Systems Market Attractiveness Analysis, by Therapeutic Area, 2022-2031
• Figure 82: Middle East & Africa Smart Drug Delivery Systems Market Analysis and Forecast, by End-user, 2021 and 2031
• Figure 83: Middle East & Africa Smart Drug Delivery Systems Market Attractiveness Analysis, by End-user, 2022-2031
• Figure 84: Middle East & Africa Smart Drug Delivery Systems Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
• Figure 85: Middle East & Africa Smart Drug Delivery Systems Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
• Figure 86: Global Smart Drug Delivery Systems Market Share Analysis/Ranking, by Company, 2021

The report provides revenue of the global smart drug delivery systems market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global smart drug delivery systems market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the smart drug delivery systems market.

The report delves into the competitive landscape of the global smart drug delivery systems market. Key players operating in the global smart drug delivery systems market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global smart drug delivery systems market profiled in this report.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Smart Drug Delivery Systems Market

4. Market Overview

• 4.1. Overview
• 4.2. Market Dynamics
  • 4.2.1. Drivers
  • 4.2.2. Restraints
  • 4.2.3. Opportunities

5. Key Insights

• 5.1. Smart Insulin Pen - Brand Analysis
• 5.2. Insulin Pen Delivery Devices Available in the U.S.
• 5.3. Insights on Digitization of Diabetes: Opportunities & Challenges
• 5.4. Key Industry Events (Partnership, Merger & Acquisition, etc.)
• 5.5. COVID-19 Impact Analysis

6. Global Smart Drug Delivery Systems Market Analysis and Forecast, by Product

• 6.1. Introduction & Definition
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Product, 2017-2031
  • 6.3.1. Connected Inhalers
  • 6.3.2. Connected Autoinjectors
  • 6.3.3. Connected Pen Injectors
  • 6.3.4. Connected Wearable Injectors
  • 6.3.5. Add-on Sensors
  • 6.3.6. Others
• 6.4. Market Attractiveness Analysis, by Product

7. Global Smart Drug Delivery Systems Market Analysis and Forecast, by Drug Delivery Mode

• 7.1. Introduction & Definition
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Drug Delivery Mode, 2017-2031
  • 7.3.1. Injectable
  • 7.3.2. Inhalation
  • 7.3.3. Oral
• 7.4. Market Attractiveness Analysis, by Drug Delivery Mode

8. Global Smart Drug Delivery Systems Market Analysis and Forecast, by Therapeutic Area

• 8.1. Introduction & Definition
• 8.2. Key Findings/Developments
• 8.3. Market Value Forecast, by Therapeutic Area, 2017-2031
  • 8.3.1. Metabolic Disorders
  • 8.3.2. Neurological Disorders
  • 8.3.3. Respiratory Disorders
  • 8.3.4. Hormonal Disorders
  • 8.3.5. Others
• 8.4. Market Attractiveness Analysis, by Therapeutic Area

9. Global Smart Drug Delivery Systems Market Analysis and Forecast, by End-user

• 9.1. Introduction & Definition
• 9.2. Key Findings/Developments
• 9.3. Market Value Forecast, by End-user, 2017-2031
  • 9.3.1. Hospitals
  • 9.3.2. Clinics
  • 9.3.3. Home Care
  • 9.3.4. Ambulatory Care Settings
  • 9.3.5. Others
• 9.4. Market Attractiveness Analysis, by End-user

10. Global Smart Drug Delivery Systems Market Analysis and Forecast, by Region

• 10.1. Key Findings
• 10.2. Market Value Forecast, by Region, 2017-2031
  • 10.2.1. North America
  • 10.2.2. Europe
  • 10.2.3. Asia Pacific
  • 10.2.4. Latin America
  • 10.2.5. Middle East & Africa
• 10.3. Market Attractiveness By Country/Region

11. North America Smart Drug Delivery Systems Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast, by Product, 2017-2031
  • 11.2.1. Connected Inhalers
  • 11.2.2. Connected Autoinjectors
  • 11.2.3. Connected Pen Injectors
  • 11.2.4. Connected Wearable Injectors
  • 11.2.5. Add-on Sensors
  • 11.2.6. Others
• 11.3. Market Value Forecast, by Drug Delivery Mode, 2017-2031
  • 11.3.1. Injectable
  • 11.3.2. Inhalation
  • 11.3.3. Oral
• 11.4. Market Value Forecast, by Therapeutic Area, 2017-2031
  • 11.4.1. Metabolic Disorders
  • 11.4.2. Neurological Disorders
  • 11.4.3. Respiratory Disorders
  • 11.4.4. Hormonal Disorders
  • 11.4.5. Others
• 11.5. Market Value Forecast, by End-user, 2017-2031
  • 11.5.1. Hospitals
  • 11.5.2. Clinics
  • 11.5.3. Home Care
  • 11.5.4. Ambulatory Care Settings
  • 11.5.5. Others
• 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 11.6.1. U.S.
  • 11.6.2. Canada
• 11.7. Market Attractiveness Analysis
  • 11.7.1. By Product
  • 11.7.2. By Drug Delivery Mode
  • 11.7.3. By Therapeutic Area
  • 11.7.4. By End-user
  • 11.7.5. By Country/Sub-region

12. Europe Smart Drug Delivery Systems Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast, by Product, 2017-2031
  • 12.2.1. Connected Inhalers
  • 12.2.2. Connected Autoinjectors
  • 12.2.3. Connected Pen Injectors
  • 12.2.4. Connected Wearable Injectors
  • 12.2.5. Add-on Sensors
  • 12.2.6. Others
• 12.3. Market Value Forecast, by Drug Delivery Mode, 2017-2031
  • 12.3.1. Injectable
  • 12.3.2. Inhalation
  • 12.3.3. Oral
• 12.4. Market Value Forecast, by Therapeutic Area, 2017-2031
  • 12.4.1. Metabolic Disorders
  • 12.4.2. Neurological Disorders
  • 12.4.3. Respiratory Disorders
  • 12.4.4. Hormonal Disorders
  • 12.4.5. Others
• 12.5. Market Value Forecast, by End-user, 2017-2031
  • 12.5.1. Hospitals
  • 12.5.2. Clinics
  • 12.5.3. Home Care
  • 12.5.4. Ambulatory Care Settings
  • 12.5.5. Others
• 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 12.6.1. Germany
  • 12.6.2. U.K.
  • 12.6.3. France
  • 12.6.4. Italy
  • 12.6.5. Spain
  • 12.6.6. Rest of Europe
• 12.7. Market Attractiveness Analysis
  • 12.7.1. By Product
  • 12.7.2. By Drug Delivery Mode
  • 12.7.3. By Therapeutic Area
  • 12.7.4. By End-user
  • 12.7.5. By Country/Sub-region

13. Asia Pacific Smart Drug Delivery Systems Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast, by Product, 2017-2031
  • 13.2.1. Connected Inhalers
  • 13.2.2. Connected Autoinjectors
  • 13.2.3. Connected Pen Injectors
  • 13.2.4. Connected Wearable Injectors
  • 13.2.5. Add-on Sensors
  • 13.2.6. Others
• 13.3. Market Value Forecast, by Drug Delivery Mode, 2017-2031
  • 13.3.1. Injectable
  • 13.3.2. Inhalation
  • 13.3.3. Oral
• 13.4. Market Value Forecast, by Therapeutic Area, 2017-2031
  • 13.4.1. Metabolic Disorders
  • 13.4.2. Neurological Disorders
  • 13.4.3. Respiratory Disorders
  • 13.4.4. Hormonal Disorders
  • 13.4.5. Others
• 13.5. Market Value Forecast, by End-user, 2017-2031
  • 13.5.1. Hospitals
  • 13.5.2. Clinics
  • 13.5.3. Home Care
  • 13.5.4. Ambulatory Care Settings
  • 13.5.5. Others
• 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 13.6.1. China
  • 13.6.2. Japan
  • 13.6.3. India
  • 13.6.4. Australia & New Zealand
  • 13.6.5. Rest of Asia Pacific
• 13.7. Market Attractiveness Analysis
  • 13.7.1. By Product
  • 13.7.2. By Drug Delivery Mode
  • 13.7.3. By Therapeutic Area
  • 13.7.4. By End-user
  • 13.7.5. By Country/Sub-region

14. Latin America Smart Drug Delivery Systems Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast, by Product, 2017-2031
  • 14.2.1. Connected Inhalers
  • 14.2.2. Connected Autoinjectors
  • 14.2.3. Connected Pen Injectors
  • 14.2.4. Connected Wearable Injectors
  • 14.2.5. Add-on Sensors
  • 14.2.6. Others
• 14.3. Market Value Forecast, by Drug Delivery Mode, 2017-2031
  • 14.3.1. Injectable
  • 14.3.2. Inhalation
  • 14.3.3. Oral
• 14.4. Market Value Forecast, by Therapeutic Area, 2017-2031
  • 14.4.1. Metabolic Disorders
  • 14.4.2. Neurological Disorders
  • 14.4.3. Respiratory Disorders
  • 14.4.4. Hormonal Disorders
  • 14.4.5. Others
• 14.5. Market Value Forecast, by End-user, 2017-2031
  • 14.5.1. Hospitals
  • 14.5.2. Clinics
  • 14.5.3. Home Care
  • 14.5.4. Ambulatory Care Settings
  • 14.5.5. Others
• 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 14.6.1. Brazil
  • 14.6.2. Mexico
  • 14.6.3. Rest of Latin America
• 14.7. Market Attractiveness Analysis
  • 14.7.1. By Product
  • 14.7.2. By Drug Delivery Mode
  • 14.7.3. By Therapeutic Area
  • 14.7.4. By End-user
  • 14.7.5. By Country/Sub-region

15. Middle East & Africa Smart Drug Delivery Systems Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast, by Product, 2017-2031
  • 15.2.1. Connected Inhalers
  • 15.2.2. Connected Autoinjectors
  • 15.2.3. Connected Pen Injectors
  • 15.2.4. Connected Wearable Injectors
  • 15.2.5. Add-on Sensors
  • 15.2.6. Others
• 15.3. Market Value Forecast, by Drug Delivery Mode, 2017-2031
  • 15.3.1. Injectable
  • 15.3.2. Inhalation
  • 15.3.3. Oral
• 15.4. Market Value Forecast, by Therapeutic Area, 2017-2031
  • 15.4.1. Metabolic Disorders
  • 15.4.2. Neurological Disorders
  • 15.4.3. Respiratory Disorders
  • 15.4.4. Hormonal Disorders
  • 15.4.5. Others
• 15.5. Market Value Forecast, by End-user, 2017-2031
  • 15.5.1. Hospitals
  • 15.5.2. Clinics
  • 15.5.3. Home Care
  • 15.5.4. Ambulatory Care Settings
  • 15.5.5. Others
• 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 15.6.1. GCC Countries
  • 15.6.2. South Africa
  • 15.6.3. Rest of Middle East & Africa
• 15.7. Market Attractiveness Analysis
  • 15.7.1. By Product
  • 15.7.2. By Drug Delivery Mode
  • 15.7.3. By Therapeutic Area
  • 15.7.4. By End-user
  • 15.7.5. By Country/Sub-region

16. Competition Landscape

• 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
• 16.2. Market Share Analysis, by Company (2021)
• 16.3. Company Profiles
  • 16.3.1. Abbott Laboratories
    • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.1.2. Product Portfolio
    • 16.3.1.3. Financial Overview
    • 16.3.1.4. Strategic Overview
    • 16.3.1.5. SWOT Analysis
  • 16.3.2. Adherium Ltd.
    • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.2.2. Product Portfolio
    • 16.3.2.3. Financial Overview
    • 16.3.2.4. Strategic Overview
    • 16.3.2.5. SWOT Analysis
  • 16.3.3. Amiko Digital Health Limited
    • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.3.2. Product Portfolio
    • 16.3.3.3. Financial Overview
    • 16.3.3.4. Strategic Overview
    • 16.3.3.5. SWOT Analysis
  • 16.3.4. Becton, Dickinson and Company
    • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.4.2. Product Portfolio
    • 16.3.4.3. Financial Overview
    • 16.3.4.4. Strategic Overview
    • 16.3.4.5. SWOT Analysis
  • 16.3.5. BIOCORP
    • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.5.2. Product Portfolio
    • 16.3.5.3. Financial Overview
    • 16.3.5.4. Strategic Overview
    • 16.3.5.5. SWOT Analysis
  • 16.3.6. CeQur Corporation
    • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.6.2. Product Portfolio
    • 16.3.6.3. Financial Overview
    • 16.3.6.4. Strategic Overview
    • 16.3.6.5. SWOT Analysis
  • 16.3.7. Cognita Labs
    • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.7.2. Product Portfolio
    • 16.3.7.3. Financial Overview
    • 16.3.7.4. Strategic Overview
    • 16.3.7.5. SWOT Analysis
  • 16.3.8. E3D Elcam Drug Delivery Devices
    • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.8.2. Product Portfolio
    • 16.3.8.3. Financial Overview
    • 16.3.8.4. Strategic Overview
    • 16.3.8.5. SWOT Analysis
  • 16.3.9. H&T Presspart Manufacturing Ltd.
    • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.9.2. Product Portfolio
    • 16.3.9.3. Financial Overview
    • 16.3.9.4. Strategic Overview
    • 16.3.9.5. SWOT Analysis
  • 16.3.10. HCmed Innovations Co., Ltd.
    • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.10.2. Product Portfolio
    • 16.3.10.3. Financial Overview
    • 16.3.10.4. Strategic Overview
    • 16.3.10.5. SWOT Analysis
  • 16.3.11. Medtronic plc
    • 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.11.2. Product Portfolio
    • 16.3.11.3. Financial Overview
    • 16.3.11.4. Strategic Overview
    • 16.3.11.5. SWOT Analysis
  • 16.3.12. Novo Nordisk
    • 16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.12.2. Product Portfolio
    • 16.3.12.3. Financial Overview
    • 16.3.12.4. Strategic Overview
    • 16.3.12.5. SWOT Analysis
  • 16.3.13. Phillips-Medisize
    • 16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.13.2. Product Portfolio
    • 16.3.13.3. Financial Overview
    • 16.3.13.4. Strategic Overview
    • 16.3.13.5. SWOT Analysis
  • 16.3.14. Sonceboz
    • 16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.14.2. Product Portfolio
    • 16.3.14.3. Financial Overview
    • 16.3.14.4. Strategic Overview
    • 16.3.14.5. SWOT Analysis